Wird geladen...
The survivin suppressant YM155 reverses doxorubicin resistance in osteosarcoma
Doxorubicin (DOX) is one of the widely used chemotherapeutic drugs for the treatment of human osteosarcoma (OS). However, acquisition of DOX resistance is common in patients with OS, leading to local and distant failure. In this study, we demonstrate that survivin expression is significantly upregul...
Gespeichert in:
| Veröffentlicht in: | Int J Clin Exp Med |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
e-Century Publishing Corporation
2015
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4694298/ https://ncbi.nlm.nih.gov/pubmed/26770398 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|